Myriad Genetics Inc

Stock Chart, Company Information, and Scan Results

$4.47(as of Jul 18, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Myriad Genetics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$4.47
Ticker SymbolMYGN
ExchangeNasdaq
SectorHealthcare
IndustryDiagnostics & Research
Employees2,700
CountyUSA
Market Cap$444.3M
EBIDTA-29.2M
10-Day Moving Average5.20
P/E Ratio-4.03
20-Day Moving Average5.23
Forward P/E Ratio476.19
50-Day Moving Average4.81
Earnings per Share-1.12
200-Day Moving Average11.82
Profit Margin-0.05%
RSI35.03
Shares Outstanding92.2M
ATR0.31
52-Week High29.30
Volume1,361,918
52-Week Low3.81
Most Recent Support Level4.98
Book Value704.9M
Most Recent Resistance Level5.37
P/B Ratio0.58
Upper Keltner5.93
P/S Ratio0.49
Lower Keltner4.53
Debt-to-Equity Ratio5.93
Next Earnings Date07/31/2025
Cash Surplus-59.3M
Next Ex-Dividend DateUnknown

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics Inc In Our Stock Scanner

example chart graphic
Date: Jul 18, 2025Scan Name: Mean ReversionScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 18, 2025Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 18, 2025Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 18, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 18, 2025Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 18, 2025Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 18, 2025Scan Name: 5 Consecutive Red DaysScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.